Biological Products, (No Diagnostic Substances)
Vaxcyte, Inc. (PCVX) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 37/100 — a percentile rank of Vaxcyte, Inc.’s fundamentals against Manufacturing peers.
Is Vaxcyte, Inc. overvalued? P/B looks fair vs its 5-year range.
Consensus: Buy from 11 analysts (Buy 11).
Average price target: $122.33 (+107.3% vs $59.00); range $120–$125.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 0 · Open-market sells: 9 · Net: −$1.4M
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!